{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:33Z","timestamp":1789133133899,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Isavuconazole is a triazole with broad-spectrum antifungal activity. In this post-hoc analysis of two prospective clinical trials (VITAL and SECURE), the safety and efficacy of isavuconazole in patients aged\u2009\u2265\u200965\u00a0years with invasive fungal diseases were evaluated. Patients were divided into two subgroups (\u2265\u200965 and\u2009&lt;\u200965\u00a0years). Adverse events (AEs); all-cause mortality; and overall, clinical, mycological, and radiological response were assessed. A total of 155 patients\u2009\u2265\u200965\u00a0years were enrolled in both trials. Most patients reported AEs. In the isavuconazole arm of both studies, serious AEs (SAEs) were greater in patients\u2009\u2265\u200965 versus\u2009&lt;\u200965\u00a0years: 76.7% versus 56.9% (VITAL); 61.9% versus 49.0% (SECURE). In SECURE, SAE rates were similar in the\u2009\u2265\u200965\u00a0years subgroup of both treatment arms (61.9% vs 58.1%), while in the\u2009&lt;\u200965\u00a0years subgroup the SAE rate was lower in the isavuconazole arm (49.0% vs 57.4%). In VITAL, all-cause mortality through day\u00a042 (30.0% vs 13.8%) was higher, and overall response at end of treatment (27.6% vs 46.8%) was lower in patients\u2009\u2265\u200965\u00a0years versus\u2009&lt;\u200965\u00a0years. In SECURE, all-cause mortality was similar between both subgroups, and isavuconazole (20.6% vs 17.9%) and voriconazole (22.6% vs 19.4%) treatment arms. The overall response was lower in the\u2009\u2265\u200965\u00a0years than the\u2009&lt;\u200965\u00a0years subgroup in the isavuconazole (23.7% vs 39.0%) and voriconazole (32.0% vs 37.5%) arms. The safety and efficacy of isavuconazole were better in patients\u2009&lt;\u200965 versus\u2009\u2265\u200965\u00a0years, and the safety profile was more favorable than that of voriconazole in both subgroups.<\/jats:p><jats:p><jats:italic>Clinicaltrials.gov identifier<\/jats:italic> NCT00634049 and NCT00412893.<\/jats:p>","DOI":"10.1038\/s41598-023-31788-1","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T09:03:09Z","timestamp":1682413389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-0212","authenticated-orcid":false,"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-4652","authenticated-orcid":false,"given":"Laura L.","family":"Kovanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-0795","authenticated-orcid":false,"given":"Jin Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1182","authenticated-orcid":false,"given":"Jalal A.","family":"Aram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"165","key":"31788_CR1","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"GD Brown","year":"2012","unstructured":"Brown, G. D. et al. Hidden killers: Human fungal infections. Sci. Transl. Med. 4(165), 165rv13-rv13 (2012).","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"31788_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/jof8010074","volume":"8","author":"H Dagher","year":"2022","unstructured":"Dagher, H. et al. Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant. J. Fungi (Basel) 8(1), 74 (2022).","journal-title":"J. Fungi (Basel)"},{"key":"31788_CR3","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760200430","volume":"115","author":"C Firacative","year":"2020","unstructured":"Firacative, C. Invasive fungal disease in humans: Are we aware of the real impact?. Mem. Inst. Oswaldo Cruz 115, e200430 (2020).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"4","key":"31788_CR4","first-page":"1","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin, F., Gago, S., Oladele, R. O. & Denning, D. W. Global and multi-national prevalence of fungal diseases-estimate precision. J. Fungi (Basel) 3(4), 1\u201329 (2017).","journal-title":"J. Fungi (Basel)"},{"issue":"3","key":"31788_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.FUNK-0014-2016","volume":"5","author":"JR K\u00f6hler","year":"2017","unstructured":"K\u00f6hler, J. R., Hube, B., Puccia, R., Casadevall, A. & Perfect, J. R. Fungi that infect humans. Microbiol. Spectr. 5(3), 1\u201329 (2017).","journal-title":"Microbiol. Spectr."},{"key":"31788_CR6","volume":"146","author":"Y Schmiedel","year":"2016","unstructured":"Schmiedel, Y. & Zimmerli, S. Common invasive fungal diseases: An overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med. Wkly. 146, w14281 (2016).","journal-title":"Swiss Med. Wkly."},{"issue":"Suppl 1","key":"31788_CR7","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/cir866","volume":"54","author":"G Petrikkos","year":"2012","unstructured":"Petrikkos, G. et al. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 54(Suppl 1), S23-34 (2012).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"31788_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/sj.leu.2403674","volume":"19","author":"K M\u00fchlemann","year":"2005","unstructured":"M\u00fchlemann, K., Wenger, C., Zenh\u00e4usern, R. & T\u00e4uber, M. G. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 19(4), 545\u2013550 (2005).","journal-title":"Leukemia"},{"key":"31788_CR9","unstructured":"Centers for Disease Control and Prevention. Aspergillosis Statistics 2019. Available at https:\/\/www.cdc.gov\/fungal\/diseases\/aspergillosis\/statistics.html Accessed in October 2021. (2019)."},{"issue":"1","key":"31788_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s43088-022-00245-9","volume":"11","author":"N Baten","year":"2022","unstructured":"Baten, N., Wajed, S., Talukder, A., Masum, M. H. U. & Rahman, M. M. Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients. Beni Suef Univ. J. Basic Appl. Sci. 11(1), 64 (2022).","journal-title":"Beni Suef Univ. J. Basic Appl. Sci."},{"issue":"22","key":"31788_CR11","first-page":"2248","volume":"324","author":"BM Kuehn","year":"2020","unstructured":"Kuehn, B. M. Pulmonary fungal infections affect patients with COVID-19. JAMA 324(22), 2248 (2020).","journal-title":"JAMA"},{"issue":"9","key":"31788_CR12","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.3201\/eid2709.210934","volume":"27","author":"A Patel","year":"2021","unstructured":"Patel, A. et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg. Infect. Dis. J. 27(9), 2349 (2021).","journal-title":"Emerg. Infect. Dis. J."},{"key":"31788_CR13","unstructured":"NIH-USA. Biological Sciences Curriculum Study. NIH Curriculum Supplement Series. Bethesda (MD): National Institutes of Health (US); 2007. Understanding Emerging and Re-emerging Infectious Diseases. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK20370\/. Accessed in October (2021)."},{"issue":"4","key":"31788_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1086\/322685","volume":"33","author":"CA Kauffman","year":"2001","unstructured":"Kauffman, C. A. Fungal infections in older adults. Clin. Infect. Dis. 33(4), 550\u2013555 (2001).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"31788_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 20(1), 133\u2013163 (2007).","journal-title":"Clin. Microbiol. Rev."},{"issue":"5","key":"31788_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176576","volume":"12","author":"F Barchiesi","year":"2017","unstructured":"Barchiesi, F. et al. Candidemia in the elderly: What does it change?. PLoS ONE 12(5), e0176576 (2017).","journal-title":"PLoS ONE"},{"key":"31788_CR17","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.2147\/IDR.S273946","volume":"13","author":"M Lao","year":"2020","unstructured":"Lao, M. et al. Clinical features and co-infections in invasive pulmonary aspergillosis in elderly patients. Inf. Drug Resist. 13, 3525\u20133534 (2020).","journal-title":"Inf. Drug Resist."},{"issue":"12","key":"31788_CR18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/jgs.12544","volume":"61","author":"G Dimopoulos","year":"2013","unstructured":"Dimopoulos, G. et al. Critically ill elderly adults with infection: Analysis of the extended prevalence of infection in intensive care study. J. Am. Geriatr. Soc. 61(12), 2065\u20132071 (2013).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"9","key":"31788_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40266-018-0576-9","volume":"35","author":"BGJ Dekkers","year":"2018","unstructured":"Dekkers, B. G. J. et al. Invasive candidiasis in the elderly: Considerations for drug therapy. Drugs Aging 35(9), 781\u2013789 (2018).","journal-title":"Drugs Aging"},{"key":"31788_CR20","first-page":"1199","volume":"8","author":"A Flevari","year":"2013","unstructured":"Flevari, A., Theodorakopoulou, M., Velegraki, A., Armaganidis, A. & Dimopoulos, G. Treatment of invasive candidiasis in the elderly: A review. Clin. Interv. Aging. 8, 1199\u20131208 (2013).","journal-title":"Clin. Interv. Aging."},{"key":"31788_CR21","unstructured":"WHO, World Health Organization. Ageing and health 2018, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health Accessed in October 2021."},{"key":"31788_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12879-014-0609-x","volume":"14","author":"H Wang","year":"2014","unstructured":"Wang, H. et al. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: A multicentre retrospective study. BMC Infect. Dis. 14, 609 (2014).","journal-title":"BMC Infect. Dis."},{"key":"31788_CR23","unstructured":"EMA. Cresemba. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cresemba; Accessed in October 2021 (2021)."},{"key":"31788_CR24","unstructured":"USFDA. Drug Trials Snapshots: CRESEMBA (aspergillosis). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-cresemba-aspergillosis. Accessed in October 2021 (2020)."},{"issue":"10020","key":"31788_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens, J. A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet 387(10020), 760\u2013769 (2016).","journal-title":"Lancet"},{"issue":"7","key":"31788_CR26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty, F. M. et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Inf. Dis. 16(7), 828\u2013837 (2016).","journal-title":"Lancet Inf. Dis."},{"issue":"7","key":"31788_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/myc.12769","volume":"61","author":"JR Perfect","year":"2018","unstructured":"Perfect, J. R. et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses 61(7), 420\u2013429 (2018).","journal-title":"Mycoses"},{"issue":"12","key":"31788_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw, B. et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group. Clin. Infect. Dis. 46(12), 1813\u20131821 (2008).","journal-title":"Clin. Infect. Dis."},{"issue":"Supplement 1","key":"31788_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1182\/blood-2021-150373","volume":"138","author":"X Fei","year":"2021","unstructured":"Fei, X. et al. Safety and efficacy of isavuconazole in patients aged 65 years or older with invasive fungal disease: A post-hoc analysis from the VITAL and secure studies. Blood 138(Supplement 1), 1219 (2021).","journal-title":"Blood"},{"issue":"2","key":"31788_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/gerona\/glr084","volume":"67","author":"DG Le Couteur","year":"2012","unstructured":"Le Couteur, D. G., McLachlan, A. J. & de Cabo, R. Aging, drugs, and drug metabolism. J. Gerontol. A Biol. Sci. Med. Sci. 67(2), 137\u2013139 (2012).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"4","key":"31788_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/jof6040324","volume":"6","author":"M Ellsworth","year":"2020","unstructured":"Ellsworth, M. & Ostrosky-Zeichner, L. Isavuconazole: Mechanism of action, clinical efficacy, and resistance. J. Fungi (Basel) 6(4), 324 (2020).","journal-title":"J. Fungi (Basel)"},{"issue":"1","key":"31788_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbmt.2009.08.015","volume":"16","author":"I Amigues","year":"2010","unstructured":"Amigues, I. et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl. 16(1), 46\u201352 (2010).","journal-title":"Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl."},{"issue":"9","key":"31788_CR33","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/cid\/ciz159","volume":"69","author":"AJ DiPippo","year":"2019","unstructured":"DiPippo, A. J. & Kontoyiannis, D. P. Lack of toxicity with long-term isavuconazole use in patients with hematologic malignancy. Clin. Infect. Dis. 69(9), 1624\u20131627 (2019).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"31788_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/myc.12851","volume":"62","author":"AJ DiPippo","year":"2019","unstructured":"DiPippo, A. J., Rausch, C. R. & Kontoyiannis, D. P. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses 62(1), 81\u201386 (2019).","journal-title":"Mycoses"},{"issue":"Suppl 1","key":"31788_CR35","first-page":"S30","volume":"51","author":"BV Gandhi","year":"2005","unstructured":"Gandhi, B. V. et al. Systemic fungal infections in renal diseases. J. Postgrad. Med. 51(Suppl 1), S30\u2013S36 (2005).","journal-title":"J. Postgrad. Med."},{"issue":"6","key":"31788_CR36","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/myc.12081","volume":"56","author":"RE Lewis","year":"2013","unstructured":"Lewis, R. E. et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: A 20-year autopsy study. Mycoses 56(6), 638\u2013645 (2013).","journal-title":"Mycoses"},{"issue":"5","key":"31788_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1086\/423274","volume":"39","author":"A Imhof","year":"2004","unstructured":"Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A. & Marr, K. A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39(5), 743\u2013746 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"31788_CR38","doi-asserted-by":"publisher","DOI":"10.1590\/1518-8345.1316.2800","volume":"24","author":"MC Rodrigues","year":"2016","unstructured":"Rodrigues, M. C. & Oliveira, C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: An integrative review. Rev. Lat. Am. Enferm. 24, e2800 (2016).","journal-title":"Rev. Lat. Am. Enferm."},{"issue":"9","key":"31788_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","volume":"289","author":"JH Gurwitz","year":"2003","unstructured":"Gurwitz, J. H. et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289(9), 1107\u20131116 (2003).","journal-title":"JAMA"},{"issue":"1","key":"31788_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"AH Groll","year":"2017","unstructured":"Groll, A. H. et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin. Pharmacol. Drug Dev. 6(1), 76\u201385 (2017).","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"1","key":"31788_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.285","volume":"6","author":"R Townsend","year":"2017","unstructured":"Townsend, R. et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults. Clin. Pharmacol. Drug Dev. 6(1), 44\u201353 (2017).","journal-title":"Clin. Pharmacol. Drug Dev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31788-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T10:12:32Z","timestamp":1682417552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31788-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31788"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31788-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KH was a consultant for, and ME is an employee of, Basilea Pharmaceutica International Ltd. LLK is an employee of Astellas Pharma Global Development, Inc. JJH and JY are employees of Pfizer Inc. and may hold stock\/stock options with Pfizer Inc. JAA was an employee of Pfizer Inc. when this analysis was conducted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6730"}}